Scientific Research News

Stay updated on research with press releases highlighting industry news, trends, and innovations driving scientific studies and academic research. Explore opportunities in research methodologies, peer-reviewed publications, and collaborative projects.

Sep 5, 2026 at 3:00 AM

Evinova and Lothar Medical Announce Strategic Partnership to Modernise Respiratory Clinical Trials with Unified Trial Solution

BAAR, Switzerland--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a strategic partnership with Lothar Medical to help transform the execution of respiratory clinical trials globally. Through the agreement, Evinova’s Unified Trial Solution will integrate with Lothar Medical’s respiratory devices to support a more connected, data-rich trial experience for sponsors, sites, and patients. Evinova Unified Trial Solution is a globally scaled, GxP...
Sep 4, 2026 at 7:03 PM

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s ETCAMAH® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test...
Sep 4, 2026 at 3:32 PM
Sep 4, 2026 at 8:00 AM

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent’s ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency...
Sep 4, 2026 at 8:00 AM

Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th,...
Sep 4, 2026 at 6:30 AM

Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a...
Sep 4, 2026 at 2:00 AM

BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

HANAU, Germany--(BUSINESS WIRE)--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.The BEST-LUVATA collaboration aims to further strengthen and e...
Sep 3, 2026 at 7:30 PM

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet...
Sep 3, 2026 at 6:30 PM

eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure

CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure...
Sep 3, 2026 at 5:23 PM

AI Visionary Ray Kurzweil Joins Subsense as Product and Vision Advisor

SAN FRANCISCO--(BUSINESS WIRE)--Subsense, an AI-native neurotechnology company developing non-surgical, nanoparticle-based brain-computer interfaces (BCIs), today announced that renowned inventor, futurist and AI pioneer Ray Kurzweil has joined the company as a product and vision advisor. The announcement was made at The Subsense Annual Forum – AI Meets the Brain event, which brought together leaders across AI, neuroscience, BCIs and investing to examine where brain technology is headed and how...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up